Showing 21-30 of 40 results for "".
- MHRA Grants Marketing Authorization for Incyte's Opzelura Cream for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescentshttps://practicaldermatology.com/news/mhra-grants-marketing-authorization-for-incytes-opzelura-cream-for-non-segmental-vitiligo-with-facial-involvement-in-adults-and-adolescents/2461838/The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing clearance for Incyte’s Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “Today&rs
- FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with DEBhttps://practicaldermatology.com/news/fda-approves-first-topical-gene-therapy-for-treatment-of-wounds-in-patients-with-deb/2461732/The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) g
- Incyte Scores Vitiligo Nod for Opzelura Cream in Europehttps://practicaldermatology.com/news/incyte-scores-nod-for-opzelura-cream-for-vitiligo-in-europe/2461674/The European Commission (EC) has granted a marketing authorization for Opzelura (ruxolitinib) cream15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The selective JAK1/JAK2 inhibi
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- Tarek El Hoss Named Sr. Vice President of Market Development and Sales at MedXhttps://practicaldermatology.com/news/tarek-el-hoss-named-sr-vice-president-of-market-development-and-sales-at-medx/2461287/Tarek El Hoss is MedX Health Corp.’s New Senior Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and g
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G
- DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-appoints-dr-gerald-krueger-to-scientific-advisory-board/2458059/DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in Salt Lake City, UT. He received his m
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- SPF30 Sunscreens Delay Melanoma Onset in Mouse Modelhttps://practicaldermatology.com/news/spf30-sunscreens-delay-melanoma-onset-in-mouse-model/2458601/Applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model, report researchers from The Ohio State University Comprehensive Cancer Center Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. S